Form D · Biotechnology

Principia Biopharma Inc.

South San Francisco, CA · CIK 0001510487

Offering snapshot reported Sep 5, 2018 · SEC filing

Reported sold
$50M
Offering amount: $50M
Investors reported
24
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 16, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 5, 2018Initial$49,999,978No comparison24SEC filing
Aug 4, 2015Initial$15,285,151No comparison13SEC filing
Feb 23, 2011Initial$12,116,666No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-320699

Source: Form D, filed Sep 5, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Srinivas Akkaraju Director
Srini Akkaraju, M.D., Ph.D. Director
Martin Babler Director, Executive
Daniel Becker Director
Eliot Charles Executive
Alan Colowick Director
Michael Dybbs Director
Simeon George Director
Simeon J. George, M.D. Director
Richard A. Miller, M.D. Director
Lewis J. Shuster Director
Lewis J. Shuster Director
Peter Thompson Director
Peter Thompson, M.D. Director, Executive
Nassim Usman Director
Nassim Usman, M.D. Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
400 East Jamie Court, Suite 302
South San Francisco, CA, 94080